TD Cowen has named a rare disease drugmaker one of its top small- and mid-cap (smidcap) picks for 2026, arguing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE